Zobrazeno 1 - 10
of 260
pro vyhledávání: '"Rociletinib"'
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 15, Pp 3915-3925 (2021)
Mohamed W Attwa, Ali S Abdelhameed, Adnan A Kadi Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Ali S Abdelhameed Tel +966 1146 98314Fax +966 1146 76 220Email asaber@ksu.edu.saBa
Externí odkaz:
https://doaj.org/article/9d02efdf2fb74a5cb96c2fa06d9af932
Autor:
Fanpu Zeng, Fang Wang, Zongheng Zheng, Zhen Chen, Kenneth Kin Wah To, Hong Zhang, Qian Han, Liwu Fu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 10, Iss 5, Pp 799-811 (2020)
Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approve
Externí odkaz:
https://doaj.org/article/4e912653cd6d4695a40ba6062ccbd847
Autor:
James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100114- (2021)
Introduction: The TIGER-3 (NCT02322281) study was initiated to compare the efficacy and safety of rociletinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR T790M and common EGFR-activating mutations, versus chemotherapy i
Externí odkaz:
https://doaj.org/article/3960fcdf0ad54bcf8d21572f501bc5e5
Autor:
Tran PN, Klempner SJ
Publikováno v:
Lung Cancer: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 91-97 (2016)
Phu N Tran,1 Samuel J Klempner2,3 1Division of Hematology/Oncology, University of California Irvine, Irvine, CA, 2Angeles Clinic and Research Institute, 3Cedars-Sinai Medical Center, Los Angeles, CA, USA Abstract: Patients with non-small-cell lung ca
Externí odkaz:
https://doaj.org/article/257d16dc79d6480186401d46e39d1bd1
Autor:
Stephanie Pitts, Xu Zhang, Udayan Guha, Karen E. Ross, Khoa Nguyen, Fatos Kirkali, Cathy H. Wu, Yue Qi, Meriam Bahta, Meghana Keswani, Shaojian Gao, Tapan K. Maity, Julie Cowart, Constance M. Cultraro
Publikováno v:
Cancer Res
Lung cancer is the leading cause of cancer mortality worldwide. The treatment of patients with lung cancer harboring mutant EGFR with orally administered EGFR tyrosine kinase inhibitors (TKI) has been a paradigm shift. Osimertinib and rociletinib are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e13821b632814b487c7275565b65a55a
https://doi.org/10.1158/0008-5472.can-20-2435
https://doi.org/10.1158/0008-5472.can-20-2435
Publikováno v:
Drug Design, Development and Therapy
Mohamed W Attwa, Ali S Abdelhameed, Adnan A Kadi Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Ali S Abdelhameed Tel +966 1146 98314Fax +966 1146 76 220Email asaber@ksu.edu.saBa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::009de6fde00a5b8b4ed808b7c82a8506
https://pubmed.ncbi.nlm.nih.gov/34552321
https://pubmed.ncbi.nlm.nih.gov/34552321
Autor:
Fan Chen, Xiulong Song, Jinpeng Liu, Kwok-Kin Wong, Robert M. Flight, Haikuo Zhang, Alexsandr Lukyanchuk, Kassandra J Naughton, Chi Wang, Hunter N. B. Moseley, Christine Fillmore Brainson, Abigail R Edgin
Publikováno v:
Advanced Science
Advanced Science, Vol 8, Iss 22, Pp n/a-n/a (2021)
Advanced Science, Vol 8, Iss 22, Pp n/a-n/a (2021)
Targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKIs) is one of the major precision medicine treatment options for lung adenocarcinoma. Due to common development of drug resistance to first‐ and second‐gener
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea219908ca95854c4a341f47ca53931
https://pubmed.ncbi.nlm.nih.gov/34622577
https://pubmed.ncbi.nlm.nih.gov/34622577
Publikováno v:
International Journal of Oncology
Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), and substantially improves t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::507937ed8518a131b87e6f48230470d7
https://pubmed.ncbi.nlm.nih.gov/34558640
https://pubmed.ncbi.nlm.nih.gov/34558640
Autor:
Mandip Singh, Arun K. Rishi, Nilkumar Patel, Peggy Arthur, Aragaw Gebeyehu, Sunil Kumar Surapaneni, Ebony Nottingham, Anil Kumar Kalvala, Arindam Mondal
Publikováno v:
Anticancer Res
Background/aim Tyrosine kinase inhibitors (TKIs) are used for the treatment of both wild type and mutant non-small cell lung cancer (NSCLC); however, acquired resistance is a major clinical challenge. Herein, we aimed to investigate the effects of te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45b74534d768011a0d0e59ebc3d6237e
https://pubmed.ncbi.nlm.nih.gov/34475041
https://pubmed.ncbi.nlm.nih.gov/34475041
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 1, Pp 41-51 (2019)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
AC0010 is a pyrrolopyrimidine-based irreversible inhibitor of epidermal growth factor receptor (EGFR), structurally distinct from previously reported pyrimidine-based irreversible EGFR inhibitors such as osimertinib and rociletinib. AC0010 selectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb2158422ee63b77618e58953b973ea
http://www.sciencedirect.com/science/article/pii/S1476558618304718
http://www.sciencedirect.com/science/article/pii/S1476558618304718